Gregory Conn - 12 Jan 2026 Form 4 Insider Report for PDS Biotechnology Corp (PDSB)

Reporting relationship: Chief Scientific Officer
Issuer ticker: PDSB
Reported as of: 12 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Mar 2026, 18:47:32 UTC
Prior SEC filing: 25 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Spencer Brown, Attorney-in-Fact

Key filing fact

Gregory Conn filed Form 4 for PDS Biotechnology Corp (PDSB) on 03 Mar 2026.

Key facts

This page summarizes Gregory Conn's Form 4 filing for PDS Biotechnology Corp (PDSB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2026, 18:47.

Change

Previous filing in this sequence was filed on 25 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001770008 Primary reporting owner

CONN GREGORY

Relationship: Chief Scientific Officer
Address: C/O PDS BIOTECHNOLOGY CORPORATION, 303A COLLEGE ROAD EAST, PRINCETON
Signature: /s/ Spencer Brown, Attorney-in-Fact
Signature date: 03 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PDSB transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +150,000
Change %
Price: $0.000000
Shares after: 150,000
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $0.9800
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.